Stock Financial Ratios, Dividends, Split History

APEN / Apollo Endosurgery Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)116.71
Enterprise Value ($M)115.33
Book Value ($M)56.84
Book Value / Share3.29
Price / Book2.02
NCAV ($M)3.64
NCAV / Share0.21
Price / NCAV31.55
Share Statistics
Preferred Stock Shares Outstanding 0
Common Stock Shares Outstanding 10,688,992
Common Shares Outstanding 10,695,711
Scoring Models
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.50
Return on Assets (ROA)-3.55
Return on Equity (ROE)-3.91
Balance Sheet (mrq) ($M)
Quick Ratio2.00
Current Ratio2.53
Income Statement (mra) ($M)
Grant And Royalty Revenue0.00
Research And Development Revenue Under Collaborative Agreements0.00
Operating Income-20.76
Net Income-41.17
Earnings Per Share Basic-105.69
Earnings Per Share Basic And Diluted-105.69
Earnings Per Share Diluted-105.69
Cash Flow Statement (mra) ($M)
Cash From Operations-12.90
Cash from Investing-2.17
Cash from Financing-2.17
Identifiers and Descriptors
Central Index Key (CIK)1251769

Split History

Stock splits are used by Apollo Endosurgery Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

Apollo Endosurgery's (APEN) CEO Todd Newton on Q4 2017 Results - Earnings Call Transcript

2018-03-02 seekingalpha
Good day and welcome to the Apollo Endosurgery Fourth Quarter 2017 Results Conference Call. Today's call is being recorded. And at this time, I would like to turn the conference over to Lee Ross of The Ruth Group. Please go ahead, sir. (0-1)

Second Sight Medical (EYES) in Focus: Stock Moves 12.1% Higher

2017-12-07 zacks
Second Sight Medical Products Inc. (EYES - Free Report) was a big mover last session, as the company saw its shares rise more than 12% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company for the company—as the stock is now up 6% in the past one-month time frame. (93-1)

Cogentix Medical (CGNT) in Focus: Stock Moves 6.6% Higher

2017-12-04 zacks
Cogentix Medical, Inc. (CGNT - Free Report) was a big mover last session, as the company saw its shares rise more than nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $2.60 to $3.05 in the past one-month time frame. (7-0)

Thor Industries, Andersons, Avid Technology, Marvell Technology and Splunk as Zacks Bull and Bear of the Day

2017-12-01 zacks
Chicago, IL – December 1, 2017 – Zacks Equity Research highlights Thor Industries, Inc. (THO - Free Report) as the Bull of the Day and The Andersons, Inc. (ANDE - Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Avid Technology, Inc. (AVID - Free Report) , Marvell Technology Group Ltd. (MRVL - Free Report) and Splunk, Inc. (SPLK - Free Report) . (66-0) featured highlights: Akari Therapeutics, Joint, Tailored Brands, Ardelyx and BioTime

2017-12-01 zacks
Chicago, IL – December 1, 2017 - Stocks in this week’s article Akari Therapeutics, Plc (AKTX - Free Report) , The Joint Corp. (JYNT - Free Report) , Tailored Brands, Inc. (TLRD - Free Report) ,  Ardelyx, Inc. (ARDX - Free Report) and BioTime, Inc. (BTX - Free Report) . (84-1)

CUSIP: 548910306